Results 21 to 30 of about 5,853 (155)

In Vitro Activity of Rifampin, Rifabutin, and Rifapentine against Enterococci and Streptococci from Periprosthetic Joint Infection

open access: yesMicrobiology Spectrum, 2021
After staphylococci, streptococci and enterococci are the most frequent causes of periprosthetic joint infection (PJI). MICs and minimum biofilm bactericidal concentrations of rifampin, rifabutin, and rifapentine were determined for 67 enterococcal and ...
Mariana Albano   +7 more
doaj   +1 more source

Efficacy of and Resistance to Rifaximin-based Quadruple Therapy in Eradication [PDF]

open access: yesThe Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2020
Background/Aims The treatment options for Helicobacter pylori (H. pylori) infection are in a state of flux: traditional triple therapies have started to fail, and new treatments are unable to achieve optimal eradication rates. Rifaximin and rifabutin are
Hyun Soo Kim   +9 more
doaj   +1 more source

Rifabutin for the Treatment of Helicobacter pylori Infection: A Review

open access: yesPathogens, 2020
Nowadays, apart from having to know first-line Helicobacter pylori eradication regimens well, we must also be prepared to face treatment failures. The aim of this review is to summarize the role of rifabutin in the management of H.
Javier P. Gisbert
doaj   +1 more source

Comparison of Rifabutin-Based Versus Rifampin-Based Regimens for the Treatment of Mycobacterium avium Complex: A meta-Analysis Study

open access: yesFrontiers in Pharmacology, 2021
Background: The incidence of Mycobacterium avium complex (MAC) increases as immunosuppressed conditions become more common. MAC's standard treatment regimen includes a macrolide, ethambutol, and a rifamycin, among which rifampin and rifabutin are the ...
Bahareh Hajikhani   +9 more
doaj   +1 more source

Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam.

open access: yesPLoS ONE, 2014
BackgroundRifampicin and protease inhibitors are difficult to use concomitantly in patients with HIV-associated tuberculosis because of drug-drug interactions. Rifabutin has been proposed as an alternative rifamycin, but there is concern that the current
Nguyen Thi Ngoc Lan   +15 more
doaj   +1 more source

Rifabutin-based Fourth and Fifth-line Rescue Therapy in Patients with for Helicobacter pylori Eradication Failure

open access: yesThe Korean Journal of Gastroenterology, 2017
Background/Aims: Optimized regimen has not yet been established for failures of multiple Helicobacter pylori (H. pylori) eradication. Hence, we aimed to evaluate the efficacy of rifabutin-based rescue therapy, at least after three eradication failures ...
Jihee Sung   +10 more
doaj   +1 more source

Ascorbigen — Rifabutin Toxicity Modifier

open access: yesАнтибиотики и Химиотерапия, 2020
Relevance. Indications for rifabutin use are constantly expanding. It is used in the treatment of extremely complex nosological forms of infectious diseases. However, side effects of the medication, such as gastrointestinal toxicity and myelosuppression,
E. R. Pereverzeva   +2 more
doaj   +1 more source

A rare case of adverse drug reaction and drug interaction in a human immunodeficiency virus patient

open access: yesJournal of Clinical and Scientific Research, 2021
We are reporting a case of rifabutin-induced uveitis in a woman with human immunodeficiency virus (HIV)-tuberculosis (TB) coinfection involving the right hip.
Kaza Kavya   +4 more
doaj   +1 more source

Tuberculosis-HIV treatment with rifampicin or rifabutin: are the outcomes different?

open access: yesMemorias do Instituto Oswaldo Cruz, 2019
BACKGROUND Rifamycins are a group of antibiotics mainly used in the treatment of tuberculosis (TB), however they interact with antiretroviral therapy (ART).
Carolina Arana Stanis Schmaltz   +3 more
doaj   +1 more source

Mycobactericidal activity of bedaquiline plus rifabutin or rifampin in ex vivo whole blood cultures of healthy volunteers: A randomized controlled trial. [PDF]

open access: yesPLoS ONE, 2018
Bedaquiline, an antimycobacterial agent approved for drug-resistant tuberculosis, is metabolized by CYP3A4, an hepatic enzyme strongly induced by rifampin, an essential part of drug-sensitive tuberculosis treatment.
Robert S Wallis   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy